The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison.
暂无分享,去创建一个
[1] D. Legatt,et al. Agranulocytosis after consumption of cocaine adulterated with levamisole. , 2009, Annals of internal medicine.
[2] R. Niesink,et al. Strong increase in total delta‐THC in cannabis preparations sold in Dutch coffee shops , 2005, Addiction biology.
[3] P. V. van Dijk,et al. An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants. , 2009, Addiction.
[4] S. van Calenbergh,et al. Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. , 2003, Journal of analytical toxicology.
[5] I. Spruit. Ecstasy Use and Policy Responses in the Netherlands , 1999 .
[6] G. Rossoni,et al. Diazepam protects against the enhanced toxicity of cocaine adulterated with atropine. , 2008, Journal of pharmacological sciences.
[7] D. Caldicott,et al. Underground pill testing, down under. , 2005, Forensic science international.
[8] E. Tanner‐Smith,et al. Pharmacological content of tablets sold as "ecstasy": results from an online testing service. , 2006, Drug and alcohol dependence.
[9] Robert G Carlson,et al. Sources of information about MDMA (3,4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users. , 2004, Drug and alcohol dependence.
[10] H. Neels,et al. Analysis of drugs of abuse in wastewater by hydrophilic interaction liquid chromatography–tandem mass spectrometry , 2009, Analytical and bioanalytical chemistry.
[11] Alex Gamma,et al. Is ecstasy perceived to be safe? A critical survey. , 2005, Drug and alcohol dependence.
[12] D. Korf,et al. Pill testing, ecstasy and prevention: a scientific evaluation in three European cities. , 2002 .
[13] Dong Chen,et al. Determination of 76 pharmaceutical drugs by liquid chromatography-tandem mass spectrometry in slaughterhouse wastewater. , 2009, Journal of chromatography. A.
[14] D. N. Sims,et al. Recent paramethoxyamphetamine deaths , 1998 .
[15] A. Winstock,et al. Mephedrone, new kid for the chop? , 2011, Addiction.
[16] A. Ritter. Illicit drugs policy through the lens of regulation. , 2010, The International journal on drug policy.
[17] E. Gouzoulis-Mayfrank,et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) , 2000, Journal of neurology, neurosurgery, and psychiatry.
[18] J. Fisk,et al. Users' perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study , 2006, Journal of psychopharmacology.
[19] Kelly Morris,et al. UK places generic ban on mephedrone drug family , 2010, The Lancet.
[20] E. Jaehne,et al. Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia , 2007, Psychopharmacology.
[21] Jih-Heng Li,et al. Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. , 2006, Forensic science international.
[22] S. Refstad. Paramethoxyamphetamine (PMA) poisoning; a ‘party drug’ with lethal effects , 2003, Acta anaesthesiologica Scandinavica.
[23] E. Kaa,et al. Narcotics at street level in Denmark. A prospective investigation from 1995 to 2000. , 2003, Forensic science international.
[24] J. Ramsey,et al. Analysis for Identification in Amnesty Bin Samples from Dance Venues , 2005, Therapeutic drug monitoring.
[25] D. Nutt,et al. Harms associated with psychoactive substances: findings of the UK National Drug Survey , 2010, Journal of psychopharmacology.
[26] G. Martinotti,et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002 , 2003, Human psychopharmacology.
[27] I. Spruit,et al. MONITORING SYNTHETIC DRUG MARKETS, TRENDS, AND PUBLIC HEALTH , 2001, Substance use & misuse.
[28] R. Paxton,et al. Drug education: a review of British Government policy and evidence on effectiveness. , 1999, Health education research.
[29] S. Legleye,et al. Two ways of estimating the euro value of the illicit market for cannabis in France. , 2008, Drug and alcohol review.
[30] Meelee Kim,et al. Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006 , 2010, Pharmacoepidemiology and drug safety.
[31] Fiona Measham,et al. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition , 2010 .
[32] Matthew Dunn,et al. Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users. , 2009, Drug and alcohol dependence.
[33] Fabrizio Schifano,et al. Drugs on the web; the Psychonaut 2002 EU project , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[34] Isabelle Giraudon,et al. Monitoring Ecstasy Content in France: Results From the National Surveillance System 1999–2004 , 2007, Substance use & misuse.
[35] A. Parrott. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity , 2004, Psychopharmacology.
[36] Marcel de Kort,et al. Pragmatism versus Ideology: Dutch Drug Policy Continued , 1999 .
[37] F. Ventura,et al. Ultraperformance liquid chromatography-tandem mass spectrometry analysis of stimulatory drugs of abuse in wastewater and surface waters. , 2007, Analytical chemistry.
[38] Shane Darke,et al. Adapting the Illicit Drug Reporting System (IDRS) to examine the feasibility of monitoring trends in the markets for 'party drugs'. , 2004, Drug and alcohol dependence.
[39] D. Nichols,et al. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.
[40] R. Dinsdale,et al. Illicit drugs and pharmaceuticals in the environment--forensic applications of environmental data. Part 1: Estimation of the usage of drugs in local communities. , 2009, Environmental pollution.
[41] J. Osterloh,et al. Levamisole: A Dangerous New Cocaine Adulterant , 2010, Clinical pharmacology and therapeutics.
[42] H. Goldschmidt. The NEXUS vision: an alternative to the reference value concept , 2004, Clinical chemistry and laboratory medicine.
[43] H. Sumnall,et al. The confusing case of NRG-1 , 2010, BMJ : British Medical Journal.
[44] H. Sumnall,et al. The content of ecstasy tablets: implications for the study of their long-term effects. , 2002, Addiction.
[45] J. Rehm,et al. Interventions to reduce harm associated with adolescent substance use , 2007, The Lancet.
[46] J. Ramsey,et al. A new method to monitor drugs at dance venues , 2001, BMJ : British Medical Journal.
[47] P. V. van Dijk,et al. Content of ecstasy in the Netherlands: 1993-2008. , 2009, Addiction.
[48] J. Vogel,et al. Levamisole-Induced Occlusive Necrotizing Vasculitis of the Ears After Use of Cocaine Contaminated with Levamisole , 2011, Journal of Medical Toxicology.
[49] Ettore Zuccato,et al. Estimating Community Drug Abuse by Wastewater Analysis , 2008, Environmental health perspectives.
[50] C. Banta-Green,et al. Eliminating solid phase extraction with large-volume injection LC/MS/MS: analysis of illicit and legal drugs and human urine indicators in U.S. wastewaters. , 2008, Environmental science & technology.
[51] J. Mounteney,et al. Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. , 2009, The International journal on drug policy.
[52] G. Dumyati,et al. Bilateral necrosis of earlobes and cheeks: another complication of cocaine contaminated with levamisole. , 2010, Annals of internal medicine.
[53] S. C. Lahiri,et al. Qualitative and quantitative analysis of seized street drug samples and identification of source. , 2005, Forensic science international.
[54] J. Kraner,et al. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). , 2001, Journal of analytical toxicology.